Management of neuroendocrine tumors: A meeting of experts from Latin America

Neuroendocrinology

Volumn 88, Issue 3, 2008, Pages 235-242

  Costa, F ^a   Domenichini, E ^c   Garavito, G ^e   Medrano, R ^g   Mendez, G ^d   O'Connor, J ^c   Rojas, W ^f   Torres, S ^h   Younes, R N ^a,b   Delle Fave, G ⁱ   Oberg K ^j  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO ALEXANDER FLEMING   (Argentina)

^d HOSPITAL DE GASTROENTEROLOGÍA DR CARLOS BONORINO UDAONDO   (Argentina)

^e Instituto Nacional de Cancerología   (Colombia)

^f HOSPITAL DE SAN JOSÉ   (Colombia)

^g Secretaria de Marina Mexico   (Mexico)

^h INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j UPPSALA UNIVERSITY   (Sweden)

more..

Author keywords

Interferon ; Latin America; Neuroendocrine tumors; Octreotide; Radionuclide imaging; Somatostatin receptors

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEFITINIB; IFOSFAMIDE; IMATINIB; IRINOTECAN; OCTREOTIDE; OXALIPLATIN; PASIREOTIDE; PAZOPANIB; PENTETREOTIDE; PLATINUM DERIVATIVE; SOMATOSTATIN DERIVATIVE; SORAFENIB; STREPTOZOCIN; SUNITINIB; TAXANE DERIVATIVE; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG;

ADD ON THERAPY; ALGORITHM; BRAZIL; CANCER CHEMOTHERAPY; CANCER SURGERY; CARCINOID; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS; DEPRESSION; DRUG DOSE ESCALATION; DRUG RECEPTOR BINDING; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL EXPERT; MICROSCOPY; MIDGUT; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL CARCINOMA; PANCREAS TUMOR; PRIORITY JOURNAL; SMALL CELL CARCINOMA; SOUTH AND CENTRAL AMERICA; SYSTEMIC THERAPY; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS; WORLD HEALTH ORGANIZATION;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIAGNOSTIC TECHNIQUES, ENDOCRINE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; EXPERT TESTIMONY; GASTROINTESTINAL NEOPLASMS; HEALTH PLANNING GUIDELINES; HUMANS; LATIN AMERICA; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

EID: 53849090934     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000149356     Document Type: Conference Paper

References (52)

1. Oberg K, Kvols L, Caplin M, et al: Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004;15:966-973.
2. Oberg K: Management of neuroendocrine tumours. Ann Oncol 2004;15(suppl 4):iv293-iv298.
3. Zikusoka MN, Kidd M, Eick G, et al: The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005;104:2292-2309.
4. Solcia E, Kloppel G, Sobin L (eds): Histological Typing of Endocrine Tumours. New York, Springer, 2000, pp 38-74.
5. Rindi G, Kloppel G, Alhman H, et al: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401.
6. Greenblatt DY, Shenker Y, Chen H: The utility of metaiodobenzylguanidine (MIBG) scintigraphy in patients with pheochromocytoma. Ann Surg Oncol 2008;15:900-905.
7. Adams S, Baum R, Rink T: Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25:79-83.
8. Koopmans KP, de Vries EG, Kema IP: Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006;7:728-734.
9. Koukouraki S, Strauss LG, Georgoulias V: Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:460-466.
10. Oberg K: Neuroendocrine gastrointestinal tumours. Ann Oncol 1996;7:453-463.
11. La Rosa S, Sessa F, Capella C, et al: Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 1996;429:323-333.
12. Rorstad O: Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005;89:151-160.
13. Akerstrom G, Hellman P: Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:87-109.
14. Wiedenmann B, Jensen RT, Mignon M, et al: Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg 1998;22:309-318.
15. Fendrich V, Langer P, Celik I, et al: An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 2006;244:845-851; discussion 852-853.
16. Schurr PG, Strate T, Rese K, et al: Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg 2007;245:273-281.
17. Norton JA, Kivlen M, Li M, et al: Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 2003;138:859-866.
18. Schindl M, Kaserer K, Niederle B: Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment. Arch Surg 2001;136:49-54.
19. Akerstrom G: Management of carcinoid tumors of the stomach, duodenum, and pancreas. World J Surg 1996;20:173-182.
20. Wang AY, Ahmad NA: Rectal carcinoids. Curr Opin Gastroenterol 2006;22:529-535.
21. Bernick PE, Klimstra DS, Shia J, et al: Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum 2004;47:163-169.
22. Sarmiento JM, Que FG: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003;12:231-242.
23. Lang H, Oldhafer KJ, Weimann A, et al: Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997;225:347-354.
24. Le Treut YP, Delpero JR, Dousset B, et al: Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 1997;225:355-364.
25. Routley D, Ramage JK, McPeake J, et al: Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumors of the liver. Liver Transpl Surg 1995;1:118-121.
26. Strosberg JR, Kvols LK: A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 2007;16:219-224.
27. Plockinger U, Wiedenmann B: Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab 2007;21:145-162.
28. Arnold R, Trautmann ME, Creutzfeldt W, et al: Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996;38:430-438.
29. di Bartolomeo M, Bajetta E, Buzzoni R, et al: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996;77:402-408.
30. Ruszniewski P, Ducreux M, Chayvialle JA, et al: Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 1996;39:279-283.
31. Saltz L, Trochanowski B, Buckley M, et al: Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993;72:244-248.
32. Eriksson B, Renstrup J, Imam H, et al: High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997;8:1041-1044.
33. Rubin J, Ajani J, Schirmer W, et al: Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999;17:600-606.
34. O'Toole D, Ducreux M, Bommelaer G, et al: Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770-776.
35. Ricci S, Antonuzzo A, Galli L, et al: Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol 2000;11:1127-1130.
36. Welin SV, Janson ET, Sundin A, et al: High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 2004;151:107-112.
37. Arnold R, Rinke A, Klose KJ, et al: Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005;3:761-771.
38. Faiss S, Pape UF, Bohmig M, et al: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003;21:2689-2696.
39. Fjallskog ML, Sundin A, Westlin JE, et al: Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol 2002;19:35-42.
40. Kolby L, Persson G, Franzen S, et al: Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003;90:687-693.
41. Kouvaraki MA, Ajani JA, Hoff P, et al: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-4771.
42. de Lima Lopes G Jr, Chiappori A, Simon G, et al: Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas. Cancer 2007;109:1413-1419.
43. Sun W, Lipsitz S, Catalano P, et al: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005;23:4897-4904.
44. Bajetta E, Ferrari L, Procopio G, et al: Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 2002;13:614-621.
45. Kulke MH, Stuart K, Enzinger PC, et al: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-406.
46. Bajetta E, Catena L, Procopio G, et al: Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007;59:637-642.
47. Yao JC: Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab 2007;21:163-172.
48. Clark OH, Ajani J, Benson AB 3rd, et al: Neuroendocrine tumors. J Natl Compr Canc Netw 2006;4:102-138.
49. Ramage JK, Davies AH, Ardill J, et al: Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54(Suppl 4):iv1-iv16.
50. Hemminki K, Li X: Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001;92:2204-2210.
51. Quaedvlieg PF, Visser O, Lamers CB, et al: Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol 2001;12:1295-1300.
52. Maggard MA, O'Connell JB, Ko CY: Updated population-based review of carcinoid tumors. Ann Surg 2004;240:117-122.